Real-World Clinical Outcomes of Teclistamab and Talquetamab in Relapsed/Refractory Multiple Myeloma (RRMM): A UK Single-Centre Experience

被引：0
|
作者：
Feixas, Pablo Tenorio [1 ]
Cox, Catrin [1 ]
Peer, Xavier [1 ]
Cuthill, Kirsty [1 ]
Benjamin, Reuben [2 ]
Gunawan, Arief [2 ]
Cuadrado, Maria [1 ]
de Farias, Madson Correia [1 ]
Jones, John [1 ]
Shin, Jin-Sup [1 ]
Batool, Asma [1 ]
Bowcock, Stella [1 ]
Omer, Musab [1 ]
Tawde, Prachi [1 ]
Bailey, Katharine [1 ]
机构：
[1] Kings Coll Hosp NHS Fdn Trust, London, England
[2] Kings Coll Hosp London, London, England
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-087
引用
收藏
页码：S92 / S92
页数：1
相关论文
共 50 条
  • [31] Clinical Outcomes of Teclistamab among MajesTEC-1 Eligible and Ineligible Population in the Real-World Setting for the Treatment of Relapsed/Refractory Multiple Myeloma
    Tan, Carlyn
    Derkach, Andriy
    Maclachlan, Kylee
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi
    Rajeeve, Sridevi
    Hashmi, Hamza
    Shah, Gunjan
    Scordo, Michael
    Chung, David
    Landau, Heather
    Giralt, Sergio
    Lesokhin, Alexander
    Korde, Neha
    Lin, Dee
    Wu, Bingcao
    Fowler, Jessica
    Fernandez, Mariana
    Kim, Nina
    Doyle, Margaret
    Hester, Laura
    Orozco, Jennifer
    Usmani, Saad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S91 - S92
  • [32] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience
    Hultcrantz, Malin
    Derkach, Andriy
    Hassoun, Hani
    Korde, Neha
    Maclachlan, Kylee H.
    Mailankody, Sham
    Patel, Dhwani
    Shah, Urvi A.
    Tan, Carlyn
    Akhlaghi, Theresia
    Hamadeh, Issam S.
    Chung, David J.
    Lahoud, Oscar B.
    Landau, Heather
    Scordo, Michael
    Shah, Gunjan L.
    Giralt, Sergio A.
    Lesokhin, Alexander M.
    Usmani, Saad
    BLOOD, 2022, 140 : 7246 - 7248
  • [33] Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma
    Girgis, Suzette
    Lin, Shun Xin Wang
    Pillarisetti, Kodandaram
    Verona, Raluca
    Vieyra, Diego
    Casneuf, Tineke
    Fink, Damien
    Miao, Xin
    Chen, Yang
    Stephenson, Tara
    Banerjee, Arnob
    Hilder, Brandi W.
    Russell, Jeffery
    Infante, Jeffrey
    Elsayed, Yusri
    Smit, Jennifer
    Goldberg, Jenna D.
    BLOOD ADVANCES, 2023, 7 (04) : 644 - 648
  • [34] Real-World Analysis of Teclistamab Treatment for Relapsed Refractory Multiple Myeloma in Two Belgian University Hospitals
    Jadot, Gaspard
    Depaus, Julien
    Vekemans, Marie-Christiane
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S59 - S59
  • [35] Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple Myeloma
    Costa, Bruno
    Tan, Carlyn
    Shekarkhand, Tala
    Firestone, Ross
    Jurgens, Eric
    Miller, Kevin
    Lesokhin, Alexander
    Shah, Gunjan
    Korde, Neha
    Rajeeve, Sridevi
    Chung, David
    Landau, Heather
    Scordo, Michael
    Hassoun, Hani
    Maclachlan, Kylee
    Shah, Urvi
    Hultcrantz, Malin
    Hamadeh, Issam
    Giralt, Sergio
    Mailankody, Sham
    Usmani, Saad
    Hashmi, Hamza
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S46 - S47
  • [36] Real-world Experience in Treating MM and Amyloidosis Patients with Teclistamab and Talquetamab in the Private Setting in the UK
    Correia, Nuno
    Dowling, Emma
    Roberts, Jamie
    Sive, Jonathan
    Kothari, Jaimal
    Rabin, Neil
    Popat, Rakesh
    Yong, Kwee
    Wechalekar, Ashu
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S283 - S284
  • [37] Safety and efficacy of standard of care (SOC) teclistamab (TEC) in patients with relapsed/refractory multiple myeloma (RRMM), a single center experience
    Grajales-Cruz, Ariel
    Khadka, Sushmita
    Blue, Brandon
    Hansen, Doris
    Puglianini, Omar Castaneda
    Freeman, Ciara
    De Avila, Gabriel
    Ochoa-Bayona, Leonel
    Liu, Hien
    Nishihori, Taiga
    Locke, Frederick
    Shain, Ken
    Baz, Rachid
    Alsina, Melissa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S39 - S40
  • [38] Belantamab mafodotin (belamaf) for relapsed/refractory multiple myeloma (RRMM): A real-world observational study update
    Hultcrantz, Malin
    Kleinman, David
    Vij, Ravi
    Escalante, Fernando
    Delforge, Michel
    Kotowsky, Nirali
    Bitetti, Jacopo
    Boytsov, Natalie
    Camadoo-O'Byrne, Leena
    Powers Happ, Lindsey
    Rohman, Mujib
    Germain, Guillaume
    Duh, Mei Sheng
    Laliberte, Francois
    Mahendran, Malena
    Urosevic, Ana
    Lee, Hans C.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience
    Hultcrantz, Malin
    Orozco, Jennifer
    Peterson, Tim J.
    Derkach, Andriy
    Hassoun, Hani
    Korde, Neha
    Lu, Sydney X.
    Mailankody, Sham
    Patel, Dhwani
    Shah, Urvi A.
    Tan, Carlyn
    Maclachlan, Kylee H.
    Chung, David J.
    Landau, Heather J.
    Shah, Gunjan L.
    Lahoud, Oscar B.
    Scordo, Michael
    Landgren, Ola
    Giralt, Sergio
    Lesokhin, Alexander
    BLOOD, 2021, 138
  • [40] A real-world observational study of belantamab mafodotin (belamaf) as a treatment for relapsed/refractory multiple myeloma (RRMM)
    Cavo, Michele
    Delforge, Michel
    Dimopoulos, Meletios
    Escalante, Fernando
    Hultcrantz, Malin
    Kleinman, David
    Lee, Hans
    Vij, Ravi
    Kotowsky, Nirali
    Camadoo-O'Byrne, Leena
    Bitetti, Jacopo
    D'Estrube, Tim
    Fry, Mark
    Vossen, Carla
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S166 - S167
12345